Bagwell C Bruce, Hill Beth L, Wood Brent L, Wallace Paul K, Alrazzak Muaz, Kelliher Abigail S, Preffer Frederic I
Verity Software House, Topsham, Maine.
Department of Laboratory Medicine, University of Washington, Seattle, Washington, 98195.
Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):214-26. doi: 10.1002/cyto.b.21243. Epub 2015 May 23.
Human progenitor and B-cell development is a highly regulated process characterized by the ordered differential expression of numerous cell-surface and intracytoplasmic antigens. This study investigates the underlying coordination of these modulations by examining a series of normal bone marrow samples with the method of probability state modeling or PSM.
The study is divided into two sections. The first section examines B-cell stages subsequent to CD19 up-regulation. The second section assesses an earlier differentiation stage before and including CD19 up-regulation. POST-CD19 ANTIGENIC UP-REGULATION: Statistical analyses of cytometry data derived from sixteen normal bone marrow specimens revealed that B cells have at least three distinct coordinated changes, forming four stages labeled as B1, B2, B3, and B4. At the end of B1; CD34 antigen expression down-regulates with TdT while CD45, CD81, and CD20 slightly up-regulate. At the end of B2, CD45 and CD20 up-regulate. At the end of B3 and beginning of B4; CD10, CD38, and CD81 down-regulate while CD22 and CD44 up-regulate. PRE-CD19 ANTIGENIC UP-REGULATION: Statistical analysis of ten normal bone marrows revealed that there are at least two measurable coordinated changes with progenitors, forming three stages labeled as P1, P2, and P3. At the end of P1, CD38 up-regulates. At the end of P2; CD19, CD10, CD81, CD22, and CD9 up-regulate while CD44 down-regulates slightly.
These objective results yield a clearer immunophenotypic picture of the underlying cellular mechanisms that are operating in these important developmental processes. Also, unambiguously determined stages define what is meant by "normal" B-cell development and may serve as a preliminary step for the development of highly sensitive minimum residual disease detection systems. A companion article is simultaneously being published in Cytometry Part A that will explain in further detail the theory behind PSM. Three short relevant videos are available in the online supporting information for both of these papers.
人类祖细胞和B细胞的发育是一个高度受调控的过程,其特征是众多细胞表面和胞浆内抗原有序地差异表达。本研究通过概率状态建模(PSM)方法检测一系列正常骨髓样本,以探究这些调节的潜在协调性。
本研究分为两个部分。第一部分检测CD19上调后的B细胞阶段。第二部分评估CD19上调之前及上调时的更早分化阶段。CD19抗原上调后:对来自16份正常骨髓标本的细胞计数数据进行统计分析发现,B细胞至少有三种不同的协同变化,形成四个阶段,分别标记为B1、B2、B3和B4。在B1末期,CD34抗原表达随末端脱氧核苷酸转移酶(TdT)下调,而CD45、CD81和CD20略有上调。在B2末期,CD45和CD20上调。在B3末期和B4初期,CD10、CD38和CD81下调,而CD22和CD44上调。CD19抗原上调前:对10份正常骨髓进行统计分析发现,祖细胞至少有两种可测量的协同变化,形成三个阶段,分别标记为P1、P2和P3。在P1末期,CD38上调。在P2末期,CD19、CD10、CD81、CD22和CD9上调,而CD44略有下调。
这些客观结果更清晰地展现了在这些重要发育过程中起作用的潜在细胞机制的免疫表型情况。此外,明确确定的阶段定义了“正常”B细胞发育的含义,并可能作为开发高灵敏度微小残留病检测系统的初步步骤。同时,一篇配套文章正在《细胞计数A部分》发表,将更详细地解释PSM背后的理论。这两篇论文的在线支持信息中都有三个简短的相关视频。